



LEI: 549300Q7EXQQH6KF7Z84

31 October 2025

RTW Biotech Opportunities Ltd

Royalty Funding Agreement with Savara Inc.

- *Savara announces 75m funding agreement with funds managed by RTW*
- *Subject to FDA approval of MOLBREEVI, a treatment for rare lung disease*
- *RTW Bio will participate through its investment in 4010 Royalty Fund*

RTW Biotech Opportunities Ltd (the "Company"), the London Stock Exchange-listed investment company focused on identifying transformative assets with high growth potential across the life sciences sector, is pleased to note the announcement by **Savara, Inc.** ("Savara" Nasdaq: **SVRA**) that it has entered into a 75 million royalty funding agreement with funds managed by RTW Investments, LP. RTW Bio will participate in this investment through its commitment to the RTW-managed 4010 Royalty Fund. Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases.

The funding is subject to FDA approval of Savara's lead program, MOLBREEVI, a treatment in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP), a rare disease characterised by the abnormal build-up of surfactant in the alveoli of the lungs. Assuming FDA approval, the funding will support the U.S. launch and further commercialisation of MOLBREEVI, which would be the first approved drug for autoimmune PAP.

Rod Wong, CIO of RTW Investments, said, "The pivotal clinical trial demonstrated the potential of MOLBREEVI to treat autoimmune PAP and this investment reflects our confidence in Savara and the strong commercial potential of the therapy. We are proud to partner with the Savara management team and look forward to supporting their efforts to bring this meaningful treatment to patients."

Savara's announcement can be found [here](#).

Enquiries:

RTW Investments, LP - Investment Manager

Oliver Kenyon

Woody Stileman

Krishna McCune (Investor Relations)

+44 (0)20 7959 6362

biotechopportunities@rtwfunds.com

Cadam Capital - PR & IR Partner

Lucy Clark (PR)

David Harris (Distribution)

+44 (0)7984 184 461 / lucy@cadamcapital.com

+44 (0)7368 883 211 / david@cadamcapital.com

Deutsche Numis - Joint Corporate Broker

Freddie Barnfield

Nathan Brown

+44 (0)20 7260 1000

BofA Securities - Joint Corporate Broker

Edward Peel

Alex Penney

+44 (0)20 7628 1000

Altum (Guernsey) Limited

Joanna Duquemin Nicolle

Sadie Morrison

+44 (0)1481 703 100

About RTW Biotech Opportunities Ltd:

RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.

Visit the website at www.rtwfunds.com/rtw-biotech-opportunities-ltd for more information.

The information contained in this announcement is given at the date of its publication (unless otherwise marked). No reliance may be placed for any purpose whatsoever on the information or opinions contained in this announcement or on its completeness, accuracy or fairness.

[illegible]

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

AGREAXEEDLSSFFA